Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia Continues To Take Its Toll; GSK Restructuring Will Cut $1.5 Bil., Jobs

Executive Summary

Due in part to plummeting Avandia sales, GlaxoSmithKline will cut $1.5 billion in costs through a restructuring program targeting sales and manufacturing, the firm announced in a third quarter sales and earnings call Oct. 24

You may also be interested in...



Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition

As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline

Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition

As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline

Merck Commercial Pilot Set To Fly Nationwide

Merck is rolling out a new commercial model, including a realigned sales organization, nationwide following a successful pilot program, Global Human Health President Kenneth Frazier said

Related Content

UsernamePublicRestriction

Register

PS048928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel